The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

(2018) Daisuke Matsutani et al.   Cardiovascular Diabetology

Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus

(2018) Shilpa Vijayakumar et al.   CIRCULATION

Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

(2018) Emelia J. Benjamin et al.   CIRCULATION

Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus

(2018) H. Sims et al.   DIABETIC MEDICINE

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes

(2018) Sean L. Zheng et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

(2018) Hussein Al Jobori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY

(2018) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pharmacotherapy of type 2 diabetes: An update

(2018) Jagriti Upadhyay et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

(2018) M Angelyn Bethel et al.   Lancet Diabetes & Endocrinology

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

(2018) Sam Miller et al.   Diabetes Therapy

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

(2018) Sam Miller et al.   Diabetes Therapy

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

(2017) David Fitchett et al.   EUROPEAN HEART JOURNAL

Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study

(2017) Yen-Chieh Lee et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Novel Diabetes Drugs and the Cardiovascular Specialist

(2017) Naveed Sattar et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

(2017) James L. Januzzi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study

(2017) Christianne L. Roumie et al.   Journal of the American Heart Association

SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

(2017) Gian Paolo Fadini et al.   Lancet Diabetes & Endocrinology

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

(2017) Christoph Wanner et al.   CIRCULATION

Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure

(2016) Genjiro Kimura   CIRCULATION JOURNAL

Sodium glucose cotransporter 2 inhibition in the diabetic kidney

(2016) Aleksandra Novikov et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes

(2016) Ele Ferrannini et al.   DIABETES

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

(2016) François Briand et al.   DIABETES

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

(2016) Sunder Mudaliar et al.   DIABETES CARE

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

(2016) Subodh Verma et al.   DIABETES CARE

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

(2016) F. Zaccardi et al.   DIABETES OBESITY & METABOLISM

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

(2016) Nikolaus Marx et al.   EUROPEAN HEART JOURNAL

Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective

(2016) Tushar Madaan et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

(2016) Ralph A. DeFronzo et al.   Nature Reviews Nephrology

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials

(2016) Sylvie Erpeldinger et al.   BMC Endocrine Disorders

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition

(2015) Giulia Ferrannini et al.   DIABETES CARE

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

(2015) R. Chilton et al.   DIABETES OBESITY & METABOLISM

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

(2015) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function

(2015) Aurora Merovci et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review

(2015) Varun Vaidya et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

(2015) Greg Fulcher et al.   Diabetes Therapy

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

(2015) Greg Fulcher et al.   Diabetes Therapy

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

(2014) David ZI Cherney et al.   Cardiovascular Diabetology

Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin

(2014) Takeshi Kadokura et al.   CLINICAL PHARMACOKINETICS

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

(2014) Bruce Neal et al.   DIABETES CARE

SGLT2 inhibitors in the treatment of type 2 diabetes

(2014) Farhad M. Hasan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study

(2014) Ulrik M. Mogensen et al.   DIABETOLOGIA

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Ketone body metabolism and cardiovascular disease

(2013) David G. Cotter et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure

(2013) Dean T. Eurich et al.   Circulation-Heart Failure

Cardiac Insulin-Resistance and Decreased Mitochondrial Energy Production Precede the Development of Systolic Heart Failure After Pressure-Overload Hypertrophy

(2013) Liyan Zhang et al.   Circulation-Heart Failure

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans

(2013) M. A. Abdul-Ghani et al.   DIABETES

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2013) Serge A. Jabbour et al.   DIABETES CARE

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

(2013) D. Polidori et al.   DIABETES CARE

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

(2013) R. A. DeFronzo et al.   DIABETES CARE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

(2013) David Polidori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin: an old but still the best treatment for type 2 diabetes

(2013) Lilian Beatriz Aguayo Rojas et al.   Diabetology & Metabolic Syndrome

Diabetes Care: "State of the Union"

(2012) W. T. Cefalu   DIABETES CARE

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

(2012) J. Rosenstock et al.   DIABETES CARE

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

(2012) M. Nauck et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

(2012) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

(2012) R. R. Henry et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

(2011) Jacob Lønborg et al.   EUROPEAN HEART JOURNAL

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Rosiglitazone Revisited

(2010) Steven E. Nissen et al.   ARCHIVES OF INTERNAL MEDICINE

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

(2010) M. Komajda et al.   EUROPEAN HEART JOURNAL

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury

(2009) Leo Timmers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Na+-Glucose Transporter-2 Messenger Ribonucleic Acid Expression in Kidney of Diabetic Rats Correlates with Glycemic Levels: Involvement of Hepatocyte Nuclear Factor-1α Expression and Activity

(2007) H. S. Freitas et al.   ENDOCRINOLOGY